Wire · opportunities
FDA approves new oral breast cancer drug combo that cut progression risk 62%: 6 notes
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 17 November 2026 · Fusion42 review
The FDA has approved Roche's Wilserdly (giredestrant) combined with everolimus for adults with ER-positive, HER2-negative, ESR1-mutated advanced breast cancer, showing a 62% reduction in progression risk. This approval follows positive phase 3 evERA trial results and positions Wilserdly as a key oral therapy in this breast cancer subtype, with a pending FDA decision on its adjuvant use.
This Wire brief sits within Fusion42's coverage of Biotech, and 5 sources have reported it between 16 Nov 2026 and 17 Nov 2026.
◆ ◆ The Wire takeaway
You can capitalise on emerging oral treatments for ESR1-mutated breast cancer as new regulatory approvals open market access. Prioritise partnerships that leverage this novel drug combo to serve patients resisting existing therapies.
◆ Coverage
5 sources · first reported 16 Nov 2026 · latest 17 Nov 2026
◆ Related on Wire
◆ Topics